B
Biobot Surgical
Health Tech & Medtech · Singapore · Founded 2007
A company innovating the realm of robotic-assisted biopsy and treatment for prostate cancer MoreLess
Biobot Surgical operates in the medical technology sector, specializing in robotic systems for prostate biopsies. The company's flagship product, the iSR'obot Mona Lisa, is a robotic transperineal prostate biopsy system that integrates MRI and ultrasound fusion technology. This system is designed to provide physicians with complete prostate coverage and accurate biopsy needle positioning, enhancing both precision and ease of use. The primary clients are healthcare providers, including hospitals and specialized clinics, who require advanced tools for diagnosing prostate cancer. Biobot Surgical's business model revolves around the sale and distribution of its robotic systems, along with associated software and support services. Revenue is generated through direct sales, distributorship agreements, and ongoing service contracts. The market for Biobot Surgical's products is global, with a focus on regions with high incidences of prostate cancer and advanced healthcare infrastructure.
Keywords: robotic biopsy, prostate cancer, MRI fusion, ultrasound, transperineal, precision medicine, healthcare technology, medical devices, diagnostic tools, clinical outcomes.
Company overview
Biobot Surgical company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2007
- Headquarters
- Singapore
- Employees
- 47
- Open positions
- None listed
- Dealroom signal
- 48.9
Valuation & funding
Biobot Surgical funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2026 | $16M | $120M | Kupa · astrid hill · ZIG Ventures · ClavystBio | ↗ |
| LATE VCOther financing | Apr 2025 | $8.5M | $120M | ZIG Ventures · astrid hill | ↗ |
| SERIES BOther financing | Mar 2024 | $24M | $96M | ZIG Ventures | ↗ |
| EARLY VCOther financing | Nov 2023 | $5.2M | $21M | ZIG Ventures | ↗ |
| SEEDOther financing | Jan 2011 | $0 | — | ZIG Ventures | — |
| SPINOUTOther financing | Jan 2007 | Nanyang Technological University | — |
Growth signals
Biobot Surgical website traffic
Latest recorded traffic for Biobot Surgical is 220 monthly website visits, down 85.3% over the last three months. Biobot Surgical's team grew 17.5% over the past year.
Comparisons
Biobot Surgical compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Biobot Surgical's talent
Source: Dealroom Talent Intelligence.
Investors
5 investors on Biobot Surgical's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Biobot Surgical has talent and traffic
team presence
In the news
Latest news about Biobot Surgical
Recent press, funding announcements, and product moves mentioning Biobot Surgical — open to read from the original sources.
Market sentiment
What the market is saying about Biobot Surgical
An AI-synthesized read of the highest-engagement posts about Biobot Surgical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biobot Surgical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.